Solid Biosciences Inc. financial data

Symbol
SLDB on Nasdaq
Location
Charlestown, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 03 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 794% % -26.9%
Debt-to-equity 22.8% % -0.04%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77,910,239 shares 95%
Common Stock, Shares, Outstanding 77,882,685 shares 100%
Entity Public Float $130,300,000 USD 153%
Common Stock, Value, Issued $78,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 94,417,746 shares 128%
Weighted Average Number of Shares Outstanding, Diluted 94,417,746 shares 128%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $132,960,000 USD 63.9%
General and Administrative Expense $36,739,000 USD 18.6%
Operating Income (Loss) $-169,699,000 USD -51.4%
Nonoperating Income (Expense) $2,564,000 USD -73.5%
Income Tax Expense (Benefit) $0 USD
Earnings Per Share, Basic -2 USD/shares 17.2%
Earnings Per Share, Diluted -2 USD/shares 22.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $61,364,000 USD -4.7%
Cash, Cash Equivalents, and Short-term Investments $236,100,000 USD 38%
Assets, Current $244,852,000 USD 36.4%
Property, Plant and Equipment, Net $4,356,000 USD -14%
Operating Lease, Right-of-Use Asset $22,535,000 USD -9.35%
Other Assets, Noncurrent $247,000 USD -48%
Assets $273,914,000 USD 29.3%
Accounts Payable, Current $8,429,000 USD 144%
Accrued Liabilities, Current $19,050,000 USD 44%
Liabilities, Current $36,342,000 USD 59%
Operating Lease, Liability, Noncurrent $19,624,000 USD -9.33%
Liabilities $55,966,000 USD 24.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $48,000 USD -58.6%
Retained Earnings (Accumulated Deficit) $-907,988,000 USD -22.6%
Stockholders' Equity Attributable to Parent $217,948,000 USD 30.5%
Liabilities and Equity $273,914,000 USD 29.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-31,850,000 USD -26.4%
Net Cash Provided by (Used in) Financing Activities $189,728,000 USD 76.9%
Net Cash Provided by (Used in) Investing Activities $-27,463,000 USD 28.6%
Common Stock, Shares Authorized 240,000,000 shares 100%
Common Stock, Shares, Issued 77,882,685 shares 100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $130,415,000 USD 199%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $63,288,000 USD -4.58%
Interest Paid, Excluding Capitalized Interest, Operating Activities $68,000 USD
Deferred Tax Assets, Valuation Allowance $130,690,000 USD 42.5%
Deferred Tax Assets, Gross $136,604,000 USD 38%
Operating Lease, Liability $22,946,000 USD -6.58%
Payments to Acquire Property, Plant, and Equipment $126,000 USD -15.4%
Lessee, Operating Lease, Liability, to be Paid $34,222,000 USD -10.8%
Property, Plant and Equipment, Gross $17,773,000 USD -8.19%
Operating Lease, Liability, Current $2,032,000 USD 18.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,284,000 USD 4.23%
Lessee, Operating Lease, Liability, to be Paid, Year One $4,176,000 USD -5%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $11,276,000 USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three $4,280,000 USD 3.81%
Deferred Tax Assets, Operating Loss Carryforwards $37,183,000 USD 124%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $4,364,000 USD 2.95%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $14,235,000 USD 64.8%
Interest Expense $88,000 USD -20.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%